Company: KVACU
Filing Date: 2025-12-22
Form Type: PRE 14A
Source: 0001213900-25-124633
Chunk: 21

Company: Keen Vision Acquisition Corp.
Filing Date: 2025-12-22
Form: PRE 14A
Chunk 21
---
 as General Partner at SparkLabs Saudi Arabia Fund I and SparkLabs Pakistan Fund I, focusing on advancing the
tech ecosystems in those respective geographies. Furthermore, he acts as a Venture Partner for SparkLabs Global Ventures Fund II, overseeing
investment sourcing and portfolio support. Additionally, he provides consultancy services for Spark I Acquisition Corp, a SPAC sponsored
by the SparkLabs Group, contributing to strategic planning, research, due diligence analyses, and deal structuring.

Prior
to his current engagements, Mr. Chu held executive positions at Zheng He Capital, a Hong Kong-based private equity firm, where he led
investments in notable companies such as Ping An Good Doctor and Lufax. Before his venture into finance, he successfully managed his family
business, Lawman Group International, and served as the Owner and President of Lawman Sportswear Inc., where he repositioned the Lawman
brand in China and launched the Petrol denim collection in the U.S. Presently, he holds the position of Vice President at Lawman International
Limited, overseeing property management.

Mr.
Chu started his career at Booz-Allen & Hamilton, later holding positions at Merrill Lynch and Wit Soundview. He holds a B.A. in East
Asian Studies from Harvard University.

We
believe Mr. Chu is well-qualified to serve as a member of our board of directors given his experience, industry expertise, and network.

Professor YU, Albert Cheung-Hoi, Ph.D., J.P.

Prof.
Yu, one of our independent directors since October 2021, has over 30 years of academic, industrial and entrepreneurial experience in biotech.
Prof. Yu has been a professor at Peking University since December 2001, where he researches glia and neuro-diseases. He has also served
as founder, chairman and Chief Scientific Officer of pioneering molecular diagnostic company Hai Kang Life Corporation Ltd since May 1999.

Concurrently,
Prof. Yu serves roles in 22 companies and organizations, including RNA interference (RNAi) therapeutics biopharmaceutical company Sirnaomics
Ltd (independent non-executive director since July 2021), venture capital fund CR-CP Life Science Fund Management Limited (independent
director since May 2021), international biotech convention organizer BIOHK Limited (director since February 2019), the Biotech Advisory
panel of the Stock Exchange of Hong Kong Limited (HKEX) (panel member since April 2018), the